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Abstract
Background: Coxsackievirus A16 (CVA16) is a member of the Enterovirus genus of the Picornaviridae family and it is
a major etiological agent of hand, foot, and mouth disease (HFMD), which is a common illness affecting children.
CVA16 possesses a single-stranded positive-sense RNA genome containing approximately 7410 bases. Current
understanding of the replication, structure and virulence determinants of CVA16 is very limited, partly due to
difficulties in directly manipulating its RNA genome.
Results: Two overlapping cDNA fragments were amplified by RT-PCR from the genome of the shzh05-1 strain of
CVA16, encompassing the nucleotide regions 1-4392 and 4381-7410, respectively. These two fragments were then
joined via a native XbaI site to yield a full-length cDNA. A T7 promoter and poly(A) tail were added to the 5’ and 3’
ends, respectively, forming a full CVA16 cDNA clone. Transfection of RD cells in vitro with RNA transcribed directly
from the cDNA clone allowed the recovery of infectious virus in culture. The CVA16 virus recovered from these
cultures was functionally and genetically identical to its parent strain.
Conclusions: We report the first construction and characterization of an infectious cDNA clone of CVA16. The
availability of this infectious clone will greatly enhance future virological investigations and vaccine development
for CVA16.
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Background
Coxsackievirus A16 (CVA16) and enterovirus 71 (EV71)
are major etiological agents of hand, foot, and mouth
disease (HFMD), which is a common illness in children
[1-6]. Surveillance data indicate that CVA16 and EV71
often co-circulate during HFMD outbreaks [1-3,5-8].
The illness caused by CVA16 infection is usually mild
[9], whereas EV71 infection is often associated with
severe complications such as brainstem encephalitis,
severe pulmonary edema and shock, and significant
mortality [6,10,11]. Therefore, EV71 has been the main
focus of virological investigations and vaccine develop-
ment for HFMD. However, recent reports suggest that
humans can be co-infected by CVA16 and EV71, and
carry these two viruses simultaneously [12,13]. This co-
infection may have contributed to the recently observed
recombination between CVA16 and EV71 [14,15], which
is believed to have led to the emergence of a recombi-
nant EV71 responsible for the large HFMD outbreak in
Fuyang City, China, during 2008 [15]. Furthermore,
CVA16 infection is not always benign because fatal
cases associated with CVA16 infection have been
reported [16-18]. These findings indicate the significant
importance of further investigation of CVA16 in order
to understand better and ultimately control infections
with this virus.
Both CVA16 and EV71 are members of the Entero-
virus genus of the Picornaviridae family and they pos-
sess a single-stranded positive-sense RNA genome
containing approximately 7400 bases. The CVA16 gen-
ome can be divided into 5’-non-coding, protein coding,
and 3’-non-coding regions [19]. The 5’-non-coding
region is ~740 nucleotides in length and it contains
genetic elements required for genome replication and
translation, for example, an internal ribosome entry site
(IRES). The 3’-non-coding region is ~100 nucleotides in
length and it is followed by a 3’ poly(A) tail. The protein
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frame that encodes a large polyprotein containing struc-
tural (P1) and non-structural (P2 and P3) regions [19].
Recent efforts have been directed toward the under-
standing of the expression, processing, and function of
CVA16-encoded proteins. For example, the use of a
panel of polyclonal antibodies against the recombinant
capsid subunit proteins of CVA16 demonstrated that P1
can be processed by CVA16-encoded proteases to yield
the subunit proteins VP0, VP1 and VP3, all of which
subsequently co-assemble to form viral capsids [20].
However, further dissection and characterization of the
role of individual viral proteins and genetic elements has
been hindered by the difficulty of directly manipulating
the RNA genome of CVA16.
F o rm a n yR N Av i r u s e s ,c D N Ac l o n e so ft h ee n t i r e
viral genome can serve as a template for the generation
of infectious RNA. These infectious cDNA clones pro-
vide a platform for the manipulation of viral genomes
a n dt h e yp r o v i d eav a l u a b l et o o lf o rs t u d y i n gt h em o l e -
cular biology of virus replication, virus structure, viru-
lence determinants, and vaccine development. Infectious
cDNA clones have been successfully developed for a
number of enteroviruses, including poliovirus [21], cox-
sackievirus B6 [22], coxsackievirus B2 [23], echovirus 5
[24], and enterovirus 71 [25-27], but not for CVA16. In
this paper, we report the first construction of an infec-
tious cDNA clone of CVA16. This infectious clone con-
tains the full-length cDNA of CVA16 flanked by a T7
promoter and a poly(A) tail at the 5’ and 3’ ends,
respectively. Transfection of RD cells with RNA tran-
scribed directly from the cDNA clone resulted in the
successful recovery of infectious virus. The recovered
CVA16 was found to be functionally and genetically
identical to its parent strain, and it could be used to
facilitate future virological investigation as well as vac-
cine development for CVA16.
Results
Construction of a full-length infectious clone of CVA16
T h eg e n o m eo ft h eC V A 1 6s t r a i ns h z h 0 5 - 1( G e n B a n k :
EU262658) is an RNA molecule containing 7410 nucleo-
tides. Viral RNA was extracted and subjected to reverse
transcription using oligo(dT) primers. Two overlapping
cDNA fragments were amplified from the first strand
cDNA, encompassing nucleotides 1-4392 and 4381-7410
of the CVA16 genome, designated as CV(1-4392) and
CV(4381-7410), respectively (Figure 1). These two over-
lapping fragments were then joined via an XbaIs i t ea t
position 4387-4392, and ligated into pcDNA3.1, result-
ing in the production of pcDNA3.1-CV(1-7410). CV
(6087-7410-pA), which contains nucleotides 6087-7410
and a poly(A) tail, was also amplified (Figure 1) and
used to replace the corresponding segment within
pcDNA3.1-CV(1-7410), thereby yielding pcDNA3.1-CV
(1-7410-pA). Sequencing analysis of the pcDNA3.1-CV
(1-7410-pA) revealed three nucleotide mutations at
positions 2733 (C to T), 2760 (T to C), and 3161 (G to
A) within the cDNA when compared with the previously
reported sequence (GenBank #EU262658). All three
mutations resulted in amino acid changes. The entire
cDNA cloning process was repeated, starting from RNA
isolation from the same batch of virus. Three clones
from two independent cloning events were fully
sequenced and the identical mutations were found in all
three clones. Thus, these three mutations were not
introduced during the cloning process. Instead, they
were likely to have been acquired during multiple
A 
B 
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Figure 1 Construction of a full-length infectious clone of
CVA16. (A) PCR amplification of CVA16 specific fragments. Lane M,
DL5000 DNA marker (TaKaRa Biotechnology, Dalian, China); lane 1,
CV(1-4392); lane 2, CV(4381-7410); and lane 3, CV(6087-7410-pA). (B)
PCR amplification of the CVA16 full-length cDNA plus T7 promoter
and 3’ poly(A) sequence. Lane M, DL15000 DNA marker (TaKaRa
Biotechnology, Dalian, China); lane 1, T7-CV(1-7410-pA) amplicon. (C)
Schematic representation of the plasmid pMD19-CV. T7, T7
promoter; CV(1-7410), nucleotides 1-7410 of the CVA16 genome; pA,
poly(A) sequence.
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report [28].
To facilitate in vitro transcription, a T7 promoter was
added upstream of CV(1-7410-pA) by PCR amplification
with primers P6 and P7 (Table 1). The resultant PCR
product with an expected size of ~7.5 Kb (Figure 1) was
cloned into the pMD19-T Simple Vector yielding
pMD19-CV, a full-length cDNA clone of CVA16. A
schematic representation of pMD19-CV is shown in Fig-
ure 1.
Recovery of infectious CVA16 from the cDNA clone
PMD19-CV was linearized by NotI digestion and used as
a template for in vitro transcription with T7 RNA poly-
merase as described in the Materials and Methods. As
shown in Figure 2, a ~7.5 Kb band was present in the in
vitro transcription reaction mixture with T7 RNA poly-
merase, but not without T7 RNA polymerase, indicating
that the band represented RNA transcripts produced
from the cDNA clone. The resultant transcripts were
used to transfect RD cells. At 72 h post-transfection,
cells and supernatants were harvested and analyzed by
microscopy and biochemical assays.
Lysates were made from transfected cells and sub-
jected to western blot analysis using a polyclonal anti-
body against the recombinant VP1 protein of CVA16 to
facilitate the detection of viral protein [20]. As shown in
Figure 3, a positive signal was not detected in the mock-
transfected sample (lane 1), whereas positive bands at
~33KDa were evident in the RNA transfected (lane 2)
and the wild-type virus-infected cell lysates (lane 3),
indicating the production of correctly processed VP1.
The presence of negative-strand viral RNA in the
transfected cells was then determined. Primer P7 (Table
1), which is complementary to the negative-strand RNA,
was used to prime the synthesis of first strand cDNA,
while the primer pair P8/P9 (Table 1) was subsequently
used to amplify the nucleotide region 2447-3328. As
s h o w ni nF i g u r e4 ,aP C Rp r o d u c to f~ 0 . 9K bw a s
observed with both the RNA transfected and wild-type
virus-infected samples. In contrast, the negative control
(mock transfected sample) did not produce a specific
PCR product. This result indicates that the RNA tran-
script transfected cells synthesized negative-strand viral
RNA as did the wild-type virus-infected cells.
The cytopathic effects (CPE) of RNA transfected cells
were observed as an indicator of productive virus infec-
tion. As shown in Figure 5, the control (mock-trans-
fected) cells appeared to grow normally, whereas the
RNA transfected cells displayed typical CPE (including
cell rounding, aggregation, and floatation) as did the
cells infected by the wild-type virus. Lysates from RNA
transfected cells were subsequently used to inoculate
RD cells. At 24 ~ 48 h post-inoculation, the lysate-
inoculated cells also exhibited severe CPE (Figure 5),
indicating that the lysate contained a first generation of
recovered virus (designated as R1), which could effi-
ciently infect permissive cells to produce a second gen-
eration of recovered virus (designated as R2). The
genome of the R1 virus was sequenced and compared to
that of the cDNA clone. The sequences were identical
(data not shown). Further infection with the R2 virus
also caused CPE in RD cells (data not shown). Overall,
the above results demonstrate that the RNA transcribed
from the CVA16 cDNA clone was capable of generating
infectious CVA16.
Characterization of the recovered CVA16
Recovered CVA16 was characterized by immunofluores-
cence. As shown in Figure 6, R1 virus-infected cells
were specifically stained using three different anti-
CVA16 polyclonal antibodies, but not using preimmune
serum. Positive signals appeared to localize in the cyto-
plasm, which was a similar pattern to that observed for
the wild-type CVA16-infected cells (Figure 6). This
result indicates that the recov e r e dv i r u sc o u l dp r o d u c e
viral proteins specific to CVA16 in a manner indistin-
guishable from the wild-type virus.
Table 1 Primers used in this study
Primer Sequence (5’ -3 ’) Enzyme site Purpose
P1 GCCAAGCTTAAAACAGCCTGTGGGTTGTTCCCACCC Hind III CV(1-4392) amplification
P2 CGGGTCTAGAGCGTAGACTCTTTTGGCTTCAGTC Xba I CV(1-4392) amplification
P3 CTACGCTCTAGAAAGAAGGA Xba I CV(4381-7410) amplification
P4 ACAAGCGGCCGCTGCTATTCTGGTTATAAC Not I CV(4381-7410) amplification
P5 CTTCTCGAGGTTGATTTTGAGCAAGCATTG Xho I CV(6087-7410-pA) amplification
P6 TATGCGGCCGCTTTTTTTTTTTTTTTTTTTTTTTTT Not I CV(6087-7410-pA) amplification
P7 CTAAAGCTTAGCTAATACGACTCACTATAGTTAAAACAGCCTGTGGGTTG Hind III T7 promoter introduction/priming
cDNA synthesis from negative-strand RNA
P8 CCTATTGCAGACATGATTGACCAG none RT-PCR for negative-strand RNA
P9 TGTTGTTATCTTGTCTCTACTAGTG none RT-PCR for negative-strand RNA
Restriction enzyme sites are underlined
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Page 3 of 8The capsid composition of the R1 virus was analyzed
by western blotting using the same polyclonal antibodies
against VP0, VP1 and VP3 of CVA16. As shown in Fig-
ure 7, the R1 virus samples produced positive signals at
positions identical to those produced by the parent
strain, suggesting no difference in the viral protein
expression or processing of both viruses.
The biological characteristics of the wild-type and
recovered viruses were also compared. The R1 virus was
found to generate the same negative-strand viral RNA
as the wild-type virus, as demonstrated by the amplifica-
tion of a ~0.9 Kb RT-PCR product from the R1 virus
(data not shown) and the wild-type virus-infected cells
(Figure 4). R1 virus-infected cells were then found to
display typical CPE (including cell rounding, aggrega-
tion, and floatation) (Figure 5). The R1 virus-induced
CPE was indistinguishable from that of the wild-type
virus (Figure 5). Moreover, the R1 virus plaque pheno-
type was similar to that of the wild-type strain (Figure
8).
Discussion
The aim of this study was to construct an infectious
clone of CVA16. The genome of CVA16 is an RNA
molecule measuring 7410 bases in length. In our study,
viral RNA was reverse transcribed to yield first-strand
cDNA, which was then used subsequently as a template
M 1  2  3 
2000
bp
1000
750
500
Figure 4 Detection of negative-sense RNA by RT-PCR.R N A
extracted from transfected or infected cells was subjected to
reverse transcription with the primer P7 and subsequent PCR
amplification of an 882-bp fragment using primers P8 and P9. Lane
M, DNA marker; lane 1, PCR product of mock-transfected cells; lane
2, PCR product of RNA-transfected cells; lane 3, PCR product of wild-
type virus infected cells.
C D 
A  B 
Figure 5 Phenotypic characteristics of RD cells post-treatment.
(A) normal RD cells; (B) RD cells infected with wild-type CVA16; (C)
RD cells transfected with in vitro-generated RNA transcripts; (D)R D
cells infected with recovered CVA16.
M 1 2 3 
35
25
KDa
VP1
Figure 3 Detection of VP1 expression in cell lysates by
Western blotting. Protein samples were separated on a 12%
polyacrylamide gel and then transferred onto a PVDF membrane.
The membrane was probed with a polyclonal antibody against the
VP1 protein of CVA16, followed by a corresponding horseradish
peroxidase-conjugated secondary antibody. Lane M, protein marker;
lane 1, mock-transfected cell lysate; lane 2, RNA-transfected cell
lysate; lane 3, wild-type virus infected cell lysate.
Figure 2 Analysis of in vitro generated RNA transcripts by
agarose gel electrophoresis. NotI linearized pMD19-CV was
transcribed with or without T7 RNA polymerase. The resultant
reaction mixtures were analyzed by electrophoresis on a 1.2%
agarose gel. Lane M, ssRNA ladder marker (Cat#N0362S, New
England Biolabs); lane 1, reaction mixture with T7 RNA polymerase;
lane 2, reaction mixture without T7 RNA polymerase.
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Page 4 of 8for the PCR amplification of CVA16-specific fragments.
Two strategies were adopted to obtain a full-length
cDNA clone of CVA16. The first was to directly amplify
the full-length CV(1-7410) from the reversely
transcribed cDNA, while the other was to amplify two
fragments, i.e., CV(1-4392) and CV(4381-7410), and
subsequently rejoin them via an XbaI site, to yield CV
(1-7410). The first strategy is successful for the con-
struction of infectious clones of a number of entero-
viruses [23,24,29], including the closely related EV71
[27], but it failed for CVA16 in this study (data not
shown). However, when we used the latter strategy, we
found that CV(1-4392) and CV(4381-7410) could be
amplified and subsequently fused to produce CV(1-
Figure 6 Immunofluorescence staining of cells infected with the R1 virus or the wild-type virus. Infected cells were incubated with
polyclonal guinea pig anti-CVVP0 (A-C and M-O), anti-CVVP1t (D-F and P-R), anti-CVVP3 (G-I and S-U), or pre-immune serum (J-L and V-X),
followed by incubation with a FITC-conjugated goat anti-guinea pig IgG antibody. Cells were also stained with DAPI. (A, D, G, J, M, P, S and V)
images captured using a FITC filter; (B, E, H, K, N, Q, T and W) images captured using a DAPI filter; and (C, F, I, L, O, R, U and X) merged images.
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Figure 7 Western blot analysis of capsid composition of the
recovered viruses. Lysates from cells infected with the R1 or R2
generation of recovered viruses or wild-type virus, were separated
by SDS-PAGE, blotted onto PVDF membranes, and probed with
polyclonal anti-CVVP0, anti-CVVP1, or anti-CVVP3, followed by
incubation with an HRP-conjugated secondary antibody.
Wild-type CVA16 Recovered CVA16
Figure 8 Plaque phenotype of wild-type and recovered CVA16.
Ten-fold dilutions of virus suspension were inoculated into 24-well
plates containing Vero cell monolayers and incubated for 2 h at 37°
C. The plaque assay was then performed as described in the
Methods section.
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Page 5 of 87410). This suggests that the size of any target fragment
is an important factor in the successful amplification of
long PCR regions. Interestingly, CV(1-7410) and its
slightly longer form, T7-CV(1-7410-pA), were amplified
from the cloned plasmid (Figure 1), although it could
not be generated from the reverse transcribed first-
strand cDNA (data not shown). Given that the reverse
transcription reaction mixture was not homogeneous,
the purity and/or abundance of the full-length first-
strand cDNA could be critical to the successful amplifi-
cation of full-length double-stranded cDNAs.
In vitro generated RNA transcripts were transfected
into RD cells via electroporation to regenerate CVA16.
The data demonstrates that these RNA transcripts were
capable of directing viral protein expression and proces-
sing (Figure 3 and 7). It is commonly accepted that
negative-strand RNA, together with positive-strand
RNA, forms double-stranded replicative intermediates
that act as a template for further positive-strand RNA
synthesis during RNA genome replication by entero-
viruses [30,31]. Thus, the presence of negative-strand
RNA was an indicator of efficient viral RNA replication.
In this study, negative-strand RNA was detected in RD
cells transfected with in vitro synthesized positive-strand
RNA (Figure 4), indicating that the exogenous RNA
transcripts were replication competent. Furthermore,
infectious CVA16 virus was recovered from the RNA
transcript transfected cells. The resultant recovered
virus was detected using CVA16-specific antibodies (Fig-
ures 6-7) and it had the same CPE (Figure 5 and 8) as
the wild-type virus. Passage of the recovered virus in RD
cells consistently led to viral protein expression (Figure
7) and CPE (Figure 5), indicating the infectivity of the
recovered virus.
Conclusions
This study reports the first construction and characteri-
zation of a novel infectious cDNA clone of CVA16. This
cDNA clone was capable of producing the infectious
CVA16 virus, which was genetically and biologically
identical to its parent stain. The availability of a CVA16
infectious clone will greatly facilitate the investigation of
the genetic determinants of its virulence. This clone will
also allow the rapid, rational development and testing of
candidate live attenuated vaccines and antiviral thera-
peutics against CVA16.
Methods
Cells and viruses
RD and Vero cells were grown in DMEM (Gibco, Grand
Island, NY, USA) supplemented with 10% FBS, 100 U/
ml penicillin, and 100 μg/ml streptomycin at 37°C with
5% CO2. The CVA16 strain shzh05-1, described in [28],
was propagated in RD or Vero cells. Virus titers were
determined by microtitration using RD cells and
expressed as the 50% tissue culture infectious dose
(TCID50), according to the Reed-Muench method [32].
RNA extraction and reverse transcription
RNA was extracted from CVA16/shzh05-1 infected RD
cells using Trizol reagent (Invitrogen, Carlsbad, CA,
USA). The extracted RNA was reverse transcribed using
oligo(dT) primers and M-MLV reverse transcriptase to
produce cDNA (Invitrogen, Carlsbad, CA, USA), accord-
ing to the manufacturer’s instructions. The resultant
first strand cDNA was used as a template for subse-
quent PCR amplification of CVA16 genome fragments.
Primer design
Primers were designed based on the published sequence
of CVA16 strain shzh05-1 (GenBank# EU262658) (Table
1) to amplify specific fragments of the CVA16 genome.
Primers P1 and P2 were designed to amplify a cDNA
fragment encompassing nucleotides 1-4392, which was
designated CV(1-4392), and it also contained engineered
HindIII and XbaI restriction enzyme sites. Primers P3
and P4 were designed to amplify a cDNA fragment
encompassing nucleotides 4381-7410, which was desig-
nated CV(4381-7410), and it contained engineered XbaI
and NotI restriction enzyme sites. Primers P5 and P6
were designed to amplify a cDNA fragment encompass-
ing nucleotides 6087-7410 with an added poly(A) tail,
which was designated CV(6087-7410-pA). Primer P7
contained a HindIII site, a T7 promoter sequence, and
20 nucleotides of the 5’ UTR of CVA16 cDNA. It was
used to introduce the T7 promoter upstream of the full-
length cDNA for efficient in vitro transcription and to
prime the synthesis of first strand cDNA from negative-
strand viral RNA. Primer P8 anchored to the nucleo-
tides 2447-2470 of positive-sense CVA16 full-length
cDNA while P9 was complementary to the nucleotides
3304-3328 of positive-sense cDNA. Both P8 and P9
were used to detect negative-strand RNA by RT-PCR
amplification of a ~0.9 KB fragment (nucleotides 2447-
3328).
Cloning of the full-length cDNA
CV(1-4392) was amplified from the reverse transcribed
first strand cDNA using primers P1 and P2 (Table 1).
Similarly, CV(4381-7410) and CV(6087-7410-pA) were
obtained using the primer pairs P3/P4 and P5/P6 (Table
1), respectively. CV(1-4392) and CV(4381-7410) were
digested with HindIII/XbaIa n dXbaI/NotI, respectively,
and ligated into HindIII/NotI digested pcDNA3.1 to
produce pcDNA3.1-CV(1-7410). CV(6087-7410-pA) was
digested with XhoI/NotI and then used to replace the
corresponding sequence within pcDNA3.1-CV(1-7410),
resulting in pcDNA3.1-CV(1-7410-pA). The primer pair
Liu et al. Virology Journal 2011, 8:534
http://www.virologyj.com/content/8/1/534
Page 6 of 8P6/P7 (Table 1) was used for PCR amplification with
pcDNA3.1-CV(1-7410-pA) as a template to introduce
the T7 promoter for in vitro transcription. The resultant
PCR product containing an engineered T7 promoter
sequence upstream of the CV(1-7410-pA) was cloned
into the pMD19-T Simple vector (Takara Mirus Bio,
Madison, WI, USA), yielding pMD19-CV.
In vitro transcription
PMD19-CV was digested with NotI, purified and used as
the template for in vitro transcription. In vitro transcrip-
tion was performed using the Riboprobe system-T7 in
vitro transcription kit (Promega, Madison, WI, USA),
according to the manufacturer’s instructions.
Transfection
RD cells were grown in T75 flasks to 90% confluency,
harvested by centrifugation, then resuspended in OPTI-
MEM medium (Cat# 31985, Invitrogen, Carlsbad, CA,
USA). Next, 400 μL( 4×1 0
6 cells) of the cell suspension
was mixed with 10 μgo fin vitro synthesized RNA tran-
s c r i p t s .T h e s em i x t u r e sw e r ei n c u b a t e df o r3m i na t
room temperature, transferred into an electroporation
cuvette, and then subjected to electroporation at 220 V
using the GenePulser Xcell™ electroporation system
(Bio-Rad, Hercules, CA, USA). Immediately after elec-
troporation, the mixtures were resuspended in 5 ml of
DMEM supplemented with 10% FBS, transferred to a
T25 flask, and incubated at 37°C with 5% CO2 for 72 h.
RT-PCR for the detection of negative-strand RNA
Viral RNA was reverse transcribed using primer P7 to
detect negative-strand RNA (Table 1). The resultant
first strand cDNA was used as a template for PCR
amplification of a fragment (nucleotides 2447-3328)
with primers P8 and P9 (Table 1). PCR was performed
using PrimeSTAR™ HS DNA polymerase (Takara
Mirus Bio, Madison, WI, USA) with the following cycle:
94°C for 5 min, followed by 30 cycles at 94°C for 30 s,
55°C for 30 s, 72°C for 60 s, with a final extension of
72°C for 10 min in an MJ Mini™ thermal cycler (Bio-
Rad, Hercules, CA, USA).
SDS-PAGE and western blot analyses
SDS-PAGE and western blotting were performed as pre-
viously described [20]. Briefly, proteins were separated
on 12% polyacrylamide gels and transferred onto PVDF
membranes. Membranes were then probed using one of
three home-made CVA16 capsid protein-specific anti-
sera [20], followed by a corresponding horseradish per-
oxidase (HRP)-conjugated secondary antibody (Sigma,
S t .L o u i s ,M O ,U S A ) .M e m b r a n e sw e r ed e v e l o p e db y
chemiluminescence using a BeyoECL Plus kit (Cat#
P0018; Beyotime, Shanghai, China) and signals were
recorded with a LAS-4000 Luminescent Image Analyzer
(Fujifilm Life Science USA, Stamford, CT, USA).
Immunofluorescence assay
Immunofluorescent staining was performed as pre-
viously described [20], using three polyclonal antibodies
against the recombinant CVA16 capsid subunit proteins,
VP0, VP1, and VP3. Stained samples were examined on
an upright fluorescence microscope (Leica, Wetzlar,
Germany).
Plaque assay
The plaque assay was performed using 24-well plates
containing Vero cell monolayers. Ten-fold dilutions of
virus suspension were inoculated at 400 μl/well and
incubated for 2 h at 37°C. The virus suspension was
then removed and 1 ml of DMEM containing 2% FBS
and 1% low melting point (LMP) agarose (Promega,
Madison, WI, USA) was added to each well, before
incubating at 37°C. The medium was discarded after
several days and cells were fixed in 10% formaldehyde
solution then stained with 0.1% crystal violet (Sigma, St.
Louis, MO, USA).
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